Costs
Science News
- JD Bioscience Gains FDA Approval for Phase 2a Clinical Trials on Fatty Liver Drug May 30, 2025[JD Bioscience (ChosunBiz)] The Gwangju Institute of Science and Technology (GIST) noted that the new drug candidate 'GM-60106', developed by JD BioScience, received global clinical Phase IIa trial plan approval from the US FDA.
- Beam Therapeutics Announces US FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) May 30, 2025[Beam Therapeutics] Beam Therapeutics Inc. announced that the US FDA has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with AATD.
- The Subfornical Organ Is a Nucleus for Gut-Derived T Cells that Regulate Behavior May 30, 2025[Nature] Investigators showed that the subfornical organ of the brain is a nucleus for parenchymal αβ T cells in the steady-state brain in both mice and humans.
- Enhancer-Driven Gene Regulatory Networks Reveal Transcription Factors Governing T Cell Adaptation and Differentiation in the Tumor Microenvironment May 30, 2025[Immunity] Scientists revealed mechanisms of tissue-resident memory CD8+ T cell-like tumor-infiltrating lymphocytes differentiation and provide a framework for considering tissue residency in the context of CD8+ T cell heterogeneity in the tumor microenvironment.
- MicroRNA-142-3p Shuttling in Extracellular Vesicles Marks Regulatory T Cell Dysfunction in Multiple Sclerosis May 30, 2025[Science Translational Medicine] Scientists found that Treg-extracellular vesicles from healthy individuals inhibit CD4+ conventional T cells by shuttling miR-142-3p from the Treg cell to the Tconv cell.
- Peripherally Induced RORγT+ Skin-Resident Regulatory T Cells Mediate the Efficacy of Allergen-Specific Immunotherapy May 30, 2025[Science Translational Medicine] Researchers investigated the role and origin of specific Treg lineages in allergen-specific immunotherapy with human atopic dermatitis (AD) samples and with a mouse model of AD.
- Hepatitis B Virus Surface Antigen Drives T Cell Immunity through Non-Canonical Antigen Presentation in Mice May 30, 2025[Nature Communications] Using preclinical mouse models, investigators showed that, following HBsAg expression, the intrahepatic Batf3+XCR1+CCR7- conventional dendritic cell subset cDC1 presents HBsAg by MHC-I cross-dressing, driving CD8+ T cell response.
- Immunosuppressive Cytokine-Tethered Hydrogel for Treating Rheumatoid Arthritis May 30, 2025[Advanced Healthcare Materials] To address challenges with current rheumatoid arthritis therapies, an interleukin-4-tethered, hyaluronic acid-based hydrogel was developed that withstands repeated mechanical stress in the joint space while fostering an immunomodulatory environment.
- N-Glycosylated LTβR Increases the Th17/Treg Cell Ratio in Liver Cancer by Blocking RORC Ubiquitination and FOXP3 Transcription May 30, 2025[Cell Death & Disease] Investigators employed primary or subcutaneous mouse hepatocellular carcinoma (HCC) models and flow cytometry to study the impact of conditional knock-in of Ltbr on CD4+ T cell differentiation and response, particularly the Th17/Treg cell ratio, and its influence on HCC progression.
- Indolepropionic Acid Modulates the Immune Response in Allergic Rhinitis through the AKT/CEBPB/IL‑10 Signaling Pathway May 30, 2025[Molecular Medicine Reports] An experimental mouse model of allergic rhinitis was established by sensitizing and exposing the mice to allergens, followed by the administration of indolepropionic acid via gavage.